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The β-lactam antibiotic ceftazidime is one of only a handful of drugs with proven clinical 17 
efficacy against the important opportunistic human pathogen Stenotrophomonas maltophilia. 18 
Here, we show that mutations in the energy transducer TonB, encoded by smlt0009 in S. 19 
maltophilia, confer ceftazidime resistance and that smlt0009 mutants have reduced uptake 20 
of ceftazidime. This breaks the dogma that β-lactams enter Gram-negative bacteria only by 21 
passive diffusion through outer membrane porins. We also show that ceftazidime-resistant 22 
TonB mutants are cross-resistant to fluoroquinolone antimicrobials and a siderophore-23 
conjugated lactivicin antibiotic designed to target TonB-dependent uptake. This implies that 24 
attempts to improve penetration of antimicrobials into S. maltophilia by conjugating them with 25 
TonB substrates will suffer from the fact that β-lactams and fluoroquinolones co-select 26 
resistance to these novel and otherwise promising antimicrobials. Finally, we show that 27 
smlt0009 mutants already exist amongst S. maltophilia clinical isolates, and have reduced 28 
susceptibility to siderophore-conjugated lactivicin, despite the in vitro growth impairment 29 














Stenotrophomonas maltophilia is a non-fermenting Gram-negative bacillus prevalent in the 41 
environment and an important opportunistic human pathogen. In the US, it caused 4.3% of 42 
all Gram-negative bacterial infections in intensive care units between 1993 and 2004 43 
(Lockhart et al, 2007). For pneumonia, in the US, 3.3% of infections in hospitalised patients 44 
between 2004 and 2008 were caused by S. maltophilia (Jones 2010). Attributable mortality 45 
rates can be high for these serious infections, up to 37.5% (Falagas et al., 2009). It also 46 
causes a wide range of other infections and colonises the lungs of >10% of adults living with 47 
Cystic Fibrosis (Brooke, 2012). S. maltophilia clinical isolates are resistant to almost all β-48 
lactam antibiotics because of the production of two β-lactamases: L1, a subclass B3 metallo-49 
β-lactamase and L2, a class A extended spectrum β-lactamase (Gould et al., 2006). 50 
Production of L1 and L2 is co-ordinately controlled by AmpR, a LysR-type transcriptional 51 
activator and induced during β-lactam challenge of cells (Okazaki & Avison, 2008). Despite 52 
this, many S. maltophilia clinical isolates remain susceptible to the β-lactam ceftazidime 53 
because it is a relatively poor substrate for these two enzymes (Calvopiña et al., 2017). 54 
However, mutants that have acquired ceftazidime resistance can easily be identified in the 55 
laboratory, and ceftazidime resistant isolates are commonly encountered in the clinic. In 56 
many cases, these mutants hyperproduce L1 and L2 (Okazaki & Avison, 2008, Talfan et al., 57 
2013, Calvopiña & Avison, 2018) but we have previously identified ceftazidime resistant 58 
mutants that did not hyperproduce β-lactamase (Gould & Avison, 2006). It was hypothesised 59 
that these mutants might have reduced accumulation of ceftazidime (Talfan et al., 2013). 60 
The primary non-β-lactamase mediated mechanisms of β-lactam resistance in similar non-61 
fermenting bacteria such as Pseudomonas aeruginosa are increased efflux and reduced 62 
outer membrane permeability due to a reduction in the production of outer membrane porins 63 
(Castanheira et al., 2014). In Gram negative bacteria, tripartite outer membrane porins are 64 
considered the only site of entry for β-lactams, and reduced porin levels can reduced β-65 




previously been suggested unless the β-lactam is conjugated to a catechol siderophore, in 67 
which case a TonB-dependent uptake system is used (Livermore, 1987). The aim of the 68 
work reported below was to identify the mechanism of non-β-lactamase mediated 69 
ceftazidime resistance in S. maltophilia. In so doing, we have broken the dogma that states 70 
that β-lactams can only enter Gram-negative bacteria through trimeric outer membrane 71 
porins via passive diffusion. 72 
  73 
Results and Discussion 74 
Disrupting a proline-rich region in the S. maltophilia TonB energy transducer Smlt0009 is 75 
associated with ceftazidime resistance. 76 
In S. maltophilia, ceftazidime resistant mutants can be selected at high frequency (Avison et 77 
al., 2002). Around 50% of ceftazidime resistant mutants selected from S. maltophilia clinical 78 
isolate K279a do not hyperproduce β-lactamase (Talfan et al., 2013). To identify the 79 
mechanism involved, we selected additional ceftazidime resistant mutants from K279a. 80 
Mutants expressing basal β-lactamase activity were isolated at a frequency expected from 81 
our earlier work. Of these, mutants M1 and M52 are exemplars. They are not β-lactamase 82 
hyperproducers, for example in comparison with a K279a mpl mutant, which does 83 
hyperproduce β-lactamases as recently described (Calvopiña & Avison, 2018) (Table 1). 84 
Nevertheless, β-lactam susceptibility was generally reduced in M1 and M52, as shown by an 85 
observed reduction in the inhibition zone diameter around various β-lactam discs (Fig. 1A).  86 
Whole genome sequencing was performed to identify the mutations present in M1 and M52. 87 
Only one gene was found to be mutated in each. It was the same in both: smlt0009, 88 
annotated in the K279a genome sequence as encoding a ‘putative proline-rich TonB energy 89 
transducer protein’ (Crossman et al., 2008). The mutation was confirmed using high fidelity 90 
PCR sequencing. In both M1 and M52, a proline rich region in Smlt0009 situated at around 91 




(Fig. 2A). Assuming this shortening impairs protein function, and to confirm the role of this 93 
impairment in ceftazidime resistance, smlt0009 was insertionally inactivated in K279a using 94 
a suicide gene replacement methodology. K279a ∆smlt0009 was confirmed to be 95 
ceftazidime resistant (Table 1) and to have generally reduced β-lactam susceptibility (Fig. 96 
1A). Complementation of the smlt0009 mutation in all these mutants using a plasmid version 97 
of the wild-type gene in trans completely reversed ceftazidime resistance, according to disc 98 
testing (Fig 1B), confirming that this phenotype is caused by the smlt0009 mutation in the 99 
mutants tested. 100 
 101 
Disruption of smlt0009 leads to increased siderophore production and reduced susceptibility 102 
to siderophore-conjugated antimicrobials. 103 
TonB-dependent uptake systems are best known for their roles in iron-siderophore import. 104 
This process requires a complex formed by a proline rich TonB energy transducer protein 105 
(Smlt0009 in this case) with ExbB (Smlt0010) and ExbD (Smlt0011), which interacts with 106 
one or more outer membrane TonB-dependent transporters (TBDTs). Specificity occurs 107 
because the TonB energy transducer only interacts with TBDTs that have bound substrate 108 
(Wilson et al., 2016, Klebba, 2016). In this way, proton motive force, generated in the inner 109 
membrane, is transduced by ExbBD to cause rotational motion of the N-terminus of the 110 
TonB energy transducer and specific opening of any TBDT that has bound ligand, ultimately 111 
driving ligand import (Klebba, 2016).  112 
To understand more about the phenotype of M1 and M52, whole envelope proteomics was 113 
performed in comparison with K279a. This confirmed that the β-lactamases L1 and L2 are 114 
not overproduced. However, 162 proteins were identified that are significantly up or down 115 
regulated in both M1 and M52 relative to K279a; 83 are downregulated in both and 79 116 
upregulated in both (Table S1). Proteomics for K279a ∆smlt0009 (Table S2) confirmed total 117 




proteins with the Uniprot accession numbers B2FHQ4, encoded by entB, smlt2820 (Fig. 3A) 119 
and accession numbers B2FRE3-7encoded by the smlt2053-57 (fep) operon (Tables S1; 120 
S2). These upregulated Fep proteins are involved in catechol siderophore production in S. 121 
maltophilia (Nas & Cianciotto, 2017) and siderophore production was found to be 122 
significantly increased in M1, M52 and K279a ∆smlt0009 relative to K279a, as predicted 123 
from the proteomics (Figure 3B, 3C). The most likely explanation for this is that disruption of 124 
Smlt0009 reduces iron-siderophore uptake into S. maltophilia K279a, which responds to the 125 
resulting iron starvation by increases siderophore production in an attempt to obtain more 126 
iron. 127 
Siderophore-conjugation has been used as a way of increasing the penetration of 128 
antimicrobials into Gram-negative bacteria by hijacking the TonB dependent uptake system 129 
(Kline et al., 2000, Choi & McCarthy, 2018). Indeed, recently we have shown that 130 
siderophore conjugation of the γ-lactam antibiotic lactivicin (to create LTV-17) dramatically 131 
improves potency against S. maltophilia (Calvopiña et al., 2016). As expected given TonB 132 
dependence of LTV-17 uptake in other species (Starr et al., 2014), ceftazidime resistant 133 
smlt0009 (TonB) mutants M1 and M52 also have reduced susceptibility to LTV-17, as does 134 
K279a Δsmlt0009 where in each case the MIC of LTV-17 increased to ≥0.25 µg.mL-1 (Table 135 
1). A single-step mutant (KLTV) with reduced susceptibility to LTV-17 was next selected 136 
from K279a and the mutant is also resistant to ceftazidime (Table 1) and has reduced 137 
susceptibility to all tested β-lactams (Fig. 1A). KLTV whole envelope proteomics showed 138 
very similar changes to those observed in M1 and M52 (Table S3). In KLTV, like M1 and 139 
M52, there is upregulation of the siderophore biosynthesis enzymes and increased 140 
siderophore production (Fig. 3). WGS confirmed shortening of the proline-rich region in 141 
Smlt0009 in KLTV (Fig. 2A). TonB mutations are known to reduce susceptibility to 142 
siderophore conjugated antimicrobials in other species but have never previously been 143 
reported to affect β-lactam susceptibility (Hassett et al., 1996, Tomaras et al., 2013, Moynie 144 




susceptibility to the non-siderophore conjugated parent lactivicin, LTV-13 (Table 1), even 146 
though this γ-lactam is structurally related to the β-lactams (Starr et al., 2014). 147 
 148 
Pleotropic effects of Smlt0009 disruption in S. maltophilia including reduced uptake of a 149 
fluorescent dye, reduced susceptibility to fluoroquinolones and slower growth. 150 
In some bacteria, TonB complexes participate in the import of TBDT-dependent ligands in 151 
addition to iron-siderophore complexes. S. maltophilia Smlt0009 shares 50% identity with the 152 
TonB energy transducer protein from the closely related Xanthomonas campestris, a species 153 
where only 15% of TBDTs are involved in iron-siderophore-complex import (Schauer et al., 154 
2008). Interestingly, of 162 proteins differently regulated in S. maltophilia K279a M1 and 155 
M52, nineteen are putative TonB-dependent TBDT proteins (Table S1). Apparently, M1 and 156 
M52 are responding to a disruption of TonB-dependent energy transduction, which is 157 
associated with the import of many diverse ligands. In support of a more general role for 158 
TonB in S. maltophilia, envelope permeability, measured via the uptake of a fluorescent 159 
Hoescht dye, was found to be significantly reduced in smlt0009 mutants relative to K279a. 160 
Interestingly, mutant M1, with the smallest deletion in the Smlt0009 proline-rich region had 161 
the least reduction in envelope permeability (Fig. 2A, 2B). Assays of susceptibility to non-β-162 
lactam antimicrobials against K279a and the smlt0009 mutants identified reduced 163 
fluoroquinolone susceptibility, though other classes of antimicrobial were not affected by 164 
disruption of Smlt0009 (Fig. 2C). Hence a TonB-dependent system is implicated in the 165 
uptake of fluoroquinolones as well as β-lactams in S. maltophilia. 166 
Given the pleotropic effects seen and the large number of putative TonB-dependent TBDTs 167 
encoded by S. maltophilia, we suspected that there would be a growth impairment for the 168 
smlt0009 mutants even in rich medium. Growth curve assays confirmed this, with K279a 169 
growing significantly better than all mutants (p<0.0001 based on a T-test of OD600 at 12 h) 170 




the smallest deletion of Smlt0009 suffered from significantly less impairment of growth 172 
(p<0.0001 at 12 h) than the other mutants (Fig. 2A, 2D). 173 
 174 
Reduced ceftazidime uptake into S. maltophilia smlt0009 mutants and existence of these 175 
mutants amongst S. maltophilia clinical isolates. 176 
Findings reported above led us to hypothesise that in S. maltophilia, uptake of β lactams is 177 
TonB dependent. Thus, mutations in the proline rich region of Smlt0009 reduce energy 178 
dependent ceftazidime uptake and confer clinically important ceftazidime resistance. This is 179 
the first time that β lactam entry via a TonB-dependent mechanism has been proposed in 180 
any bacterium. However, it is interesting to note that, unlike all other pathogens studied 181 
previously, outer membrane passive diffusion porin loss has never been found to be involved 182 
in β-lactam resistance in S. maltophilia (Sanchez, 2015) which supports the existence of a 183 
novel import mechanism in this species. 184 
To test our hypothesis that disruption of Smlt0009 reduces ceftazidime uptake in S. 185 
maltophilia, we incubated K279a and the various smlt0009 mutants with ceftazidime and 186 
then measured the concentration of ceftazidime remaining in the growth medium by using an 187 
Escherichia coli killing assay where the lower the concentration of ceftazidime, the smaller 188 
the zone of killing seen on a lawn of E. coli DH5α. As can be seen (Fig. 4) the concentration 189 
of ceftazidime outside of K279a is significantly less than the concentration outside of the 190 
smlt0009 mutants after 24 h of incubation, confirming that ceftazidime enters K279a more 191 
readily than the smlt0009 mutants. This adds strong support to our hypothesis that 192 
ceftazidime uptake is TonB dependent in S. maltophilia. Identifying which of the >20 TBDTs 193 
seen in S. maltophilia K279a is the one responsible for ceftazidime uptake will form the basis 194 
of future work.  195 
Finally, we turned to our world-wide collection of 22-phylogenetic group A S. maltophilia 196 




LTV-13 (Table 2). One isolate, number 31, stood out as having reduced susceptibility to 198 
LTV-17 (MIC = 0.25 µg.mL-1) without altered susceptibility to LTV-13, a phenotype shared 199 
with K279a smlt0009 mutants (Tables 1, 2). Of the tested clinical isolates, thirteen had the 200 
same predicted sequence for Smlt0009 as K279a, based on PCR sequencing; eight isolates 201 
had N169S plus A209T variants of this sequence, but given it is so common this is highly 202 
likely to be random genetic drift. Isolate number 31, with reduced LTV-17 susceptibility had 203 
an insertion of a single proline in the proline-rich region of Smlt0009 (Table 2). 204 
According to our records, isolate number 31 was from a patient being treated in an intensive 205 
care unit in a Brazilian hospital in 2003. It was collected as part of the SENTRY antimicrobial 206 
surveillance programme (Toleman et al., 2007). Remarkably, isolate number 31 also carries 207 
an ampD loss of function mutation and hyper-produces both the L1 and L2 β-lactamases, 208 
which is enough to give pan β-lactam resistance without any additional mechanism (Gould et 209 
al., 2006, Talfan et al., 2013, Calvopina et al., 2017). We have reported, however, that 210 
isolate number 31 is unusual in its resistance to ceftazidime/β-lactamase inhibitor 211 
combinations (Calvopina et al., 2017), so combination therapy including a β-lactam/β-212 
lactamase inhibitor might have selected for this mutation even in a background of β-213 
lactamase hyper-production. Whatever the specifics of selection in this case, we have 214 
demonstrated the existence of S. maltophilia clinical isolates with mutations in the TonB 215 
energy transducer Smlt0009, which have reduced susceptibility to β-lactams, 216 
fluoroquinolones and siderophore-conjugated antimicrobials.  217 
 218 
Conclusions 219 
Examples of outer membrane tripartite porin loss leading to reduced β-lactam susceptibility 220 
in Gram-negative bacteria are numerous. They include important carbapenem resistance 221 
mutations such as OprD loss in P. aeruginosa (Huang et al., 1992) and OmpK36 loss in 222 




porins, and they can also be highly specific. For example, OmpK36 loss causes meropenem 224 
resistance, but does not confer resistance to the closely related carbapenem, imipenem 225 
(Findlay et al., 2012). Because of the importance of carbapenems as last-resort 226 
antimicrobials, porin loss conferring carbapenem resistance in clinical isolates was quickly 227 
identified but S. maltophilia is intrinsically resistant to all carbapenems because of the 228 
production of an inducible carbapenemase, named L1 (Calvopiña et al., 2017). Indeed, there 229 
are only six agents for which the US Clinical and Laboratory Standards Institute provide 230 
resistance/susceptibility breakpoints; indicating potential clinical efficacy (CLSI, 2017): two β-231 
lactams, ceftazidime and ticarcillin-clavulanate; a fluoroquinolone, levofloxacin; a tetracycline 232 
derivative, minocycline; a phenicol, chloramphenicol, and the drug of choice (and the only 233 
agent for which breakpoints are provided by the European Committee on Antimicrobial 234 
Susceptibility Testing) trimethoprim-sulfamethoxazole. We and others have identified 235 
mechanisms of resistance, including efflux pumps, modifying enzymes and bypass 236 
reactions, relevant to all these agents. Porin loss has not been found as a mechanism in in 237 
any case (Sanchez, 2015). Because of this, we have long suspected that antimicrobial entry 238 
into S. maltophilia may be atypical and porins may not be as important as in other clinically 239 
important species.  240 
The work presented here confirm for the first time that β-lactam antibiotics can enter Gram-241 
negative bacteria via a TonB-dependent mechanism. We also present evidence that this is 242 
true of fluoroquinolones. Whilst we have not identified the outer membrane TBDT(s) 243 
responsible for uptake, the fact that disruption of TonB reduced ceftazidime uptake to such a 244 
degree that mutants become clinically resistant, shows how important TonB-dependent 245 
uptake is to the activity of ceftazidime against this human pathogen. Since TonB-dependent 246 
uptake is very important, at the very least for iron-siderophore uptake, it was expected that 247 
disruption of TonB would cause a growth defect, and this was confirmed, even in complex 248 
medium. However, our identification of an smlt0009 (TonB) mutant clinical isolate (isolate 249 




which is resistant to 5/6 available anti-S. maltophilia antimicrobials listed above, except for 251 
minocycline (Calvopina et al., 2016), only has a very slight modification to the Smlt0009 252 
proline rich region: a single residue insertion. Given that the smaller the change to Smlt0009, 253 
the lower the effect on growth defect (e.g. see mutant M1 versus the others in Fig 2D) this 254 
hints at a trade-off between reduced entry of antimicrobials whilst allowing sufficient entry of 255 
iron-siderophores and other TonB-dependent substrates to minimise the resulting 256 
attenuation of growth.  257 
The fact that smlt0009 mutants exist in the clinic does not bode well for the long-term activity 258 
of catechol siderophore-conjugated antimicrobials, which are designed to target TonB-259 
dependent uptake, including those reported to have very good activity against extensively 260 
drug resistant S. maltophilia isolates in animal infection models (Chen et al., 2019). Indeed, 261 
our finding that catechol siderophore-conjugated lactivicin has markedly reduced activity 262 
against smlt0009 mutants, including clinical isolate 31 (Table 1, 2), confirms that resistance 263 
already exists in the clinical S. maltophilia population. In other species, TonB mutations are 264 
known to confer resistance to siderophore-conjugated antimicrobials (Tomaras et al., 2013), 265 
but the fact that β-lactams are shown here to be TonB dependent substrates, and it is likely 266 
that fluoroquinolones are as well, means that in S. maltophilia, unlike other species, TonB 267 
mutation is not only selected by the use of siderophore-conjugated antimicrobials, but also 268 
by two antimicrobial classes that have been extensively used for decades. Accordingly, as 269 
well as breaking the dogma that β-lactams only enter Gram-negative bacteria via trimeric 270 
porins, the work presented here is clinically important, both for explaining resistance to 271 
existing antimicrobials, and to consider when developing new ones. 272 
  273 




Experimental Procedures 275 
Bacterial isolates and materials 276 
S. maltophilia clinical isolates used originated from the SENTRY antimicrobial resistance 277 
survey and have been previously described (Toleman et al., 2007) plus isolate K279a 278 
(Avison et al., 2000). All growth media were from Oxoid. Chemicals were from Sigma, unless 279 
otherwise stated. LTV-13 was re synthesized according to the literature protocol (Starr et al., 280 
2014) and kindly provided by Prof. C. Schofield, University of Oxford. LTV-17 was kindly 281 
supplied by Pfizer. 282 
Selection of resistant mutants 283 
K279a ceftazidime resistant mutants were selected after exposure of lawns of bacteria to 30 284 
µg ceftazidime discs on Muller-Hinton Agar (MHA) by picking the colonies within the zone of 285 
inhibition after using a bacterial suspension that was 100-fold higher than the recommended 286 
value according to the CLSI guidelines (CLSI, 2012). Mutants with reduced susceptibility to 287 
LTV-17 were selected by plating 100 µL of an overnight culture grown in Nutrient Broth (NB) 288 
on MHA containing increasing concentrations of LTV-17. Colonies from the highest LTV-17 289 
concentration plate where growth was seen were picked. 290 
β-lactamase assays 291 
100 µL of an overnight NB culture was diluted in 10 mL of NB and incubated at 37°C with 292 
shaking until OD600 was 0.4. Cells were pelleted by centrifugation (4,000 x g, 10 min) and 293 
pellets resuspended in 100 µL of BugBuster (Ambion). Pellets were transferred to 1.5 mL 294 
microtube (Eppendorf) before rocking at 70 rpm for 30 min at room temperature. Cell debris 295 
and unlysed cells were pelleted by centrifugation (13,000 x g, 5 min) and the supernatant 296 
retained as a source of crude cell protein. Protein concentrations in cell extracts were 297 
determined using the BioRad protein assay dye reagent concentrate according to the 298 
manufacturer’s instructions. β-Lactamase activity in crude cell extracts was determined 299 




solution was used as a substrate, prepared in 0.2 µm syringe-filtered assay buffer (60 mM 301 
Na2HPO4·7H2O pH 7.0, 40 mM NaH2PO4·H2O, 10 mM KCl, 1 mM MgSO4·7H2O, 100 µM 302 
ZnCl2). Nitrocefin hydrolysis assays were performed in Corning Costar 96-well flat-bottomed 303 
cell culture plates with a combination of 1 µL of cell extract and 179 µL of nitrocefin solution. 304 
Product accumulation was measured at 482 nm for 5 min or until the end of the linear phase 305 
of the reaction. Final β-lactamase activity (nmol.min-1.µg-1 of protein in cell extract) was 306 
calculated via change in absorbance per minute taken from the linear phase of the reaction 307 
in Omega Data Analysis. An extinction coefficient of 17400 M-1cm-1 was used for nitrocefin. 308 
The path length for liquid in a well in the 96-well plate was set at 0.56 cm. 309 
Determining minimal inhibitory concentrations (MICs) of antimicrobials and disc susceptibility 310 
testing 311 
The CLSI protocol was followed for disc susceptibility testing (CLSI, 2006). The clearance 312 
zone was measured after 20 h of incubation and bacteria reported as susceptible or resistant 313 
according to CLSI published breakpoints, where available (CLSI, 2017). 314 
MICs were determined using CLSI broth microtitre assays (CLSI, 2012) and interpreted 315 
using published breakpoints (CLSI, 2017). Briefly, a PBS bacterial suspension was prepared 316 
to obtain a stock of OD600=0.01. The final volume in each well of a 96-well cell culture plate 317 
(Corning Costar) was 200 µL and included 20 µL of the bacterial suspension. Bacterial 318 
growth was determined after 20 h of incubation by measuring OD600 values using a 319 
POLARstar Omega spectrophotometer (BMG Labtech). 320 
Whole genome sequencing to Identify mutations 321 
Whole genome resequencing was performed by MicrobesNG (Birmingham, UK) on a HiSeq 322 
2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic 323 
(Bolger et al., 2014) and assembled into contigs using SPAdes 3.10.1 324 




for S. maltophilia K279a (Crossman et al., 2008) obtained from GenBank (accession number 326 
NC_010943) using progressive Mauve alignment software (Darling et al., 2010).  327 
Mutations were checked by PCR using Phusion High Fidelity DNA Polymerase (New 328 
England Biolabs). To generate template DNA, a bacterial colony was resuspended in 100 µL 329 
of molecular biology grade water and heated at 100°C for 5 min. The sample was 330 
centrifuged at 13000 rpm for 5 min. PCR reactions were set up using 5 µL of 5X Phusion GC 331 
Buffer, 0.5 µL of dNTPs (10 mM), 1.25 µL of forward primer (10 µM), 1.25 µL of reverse 332 
primer (10 µM), 0.75 µL of DMSO, 0.25 µL of Phusion DNA Polymerase, 1 µL of DNA 333 
template, and 15 µL of molecular biology grade water. The cycling conditions were the 334 
following: 1 cycle of 98°C for 30 s, 30 cycles of: 98°C for 10 s, 60°C for 15 s, and 72°C for 30 335 
s, 1 cycle of 72°C for 10 min for final extension.  336 
The primers used were: smlt0009 F 5’-GTGTGAAGAACCAGGCTGATGCCA-3’ and 337 
smlt0009 R 5’-AGGGTGTAGCTAAGCTAAACAAT-3’. PCR products were purified using the 338 
QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’s instructions. DNA 339 
concentration of purified samples was quantified using NanoDrop Lite spectrophotomer 340 
(Thermo Scientific). PCR products were sequenced by Eurofins. Sequences obtained were 341 
analysed with ClustalW OMEGA or MultiAlignPro. Alignments were represented using 342 
ESPript 3.0. 343 
Insertional inactivation of smlt0009 344 
The K279a ∆smlt0009 mutant was constructed by gene inactivation mediated by the 345 
pKNOCK suicide plasmid (Alexeyev, 1999). The smlt0009 DNA fragment was amplified with 346 
Phusion High-Fidelity DNA Polymerase (NEB, UK) from S. maltophilia genomic DNA by 347 
using primers smlt0009 KO FW (5′-GTGAAGAATCTGTCGCCGC-3′) and smlt0009 KO RV 348 
(5′-GGATCACTTCGCCCTGGATA-3′). The PCR product was ligated into the pKNOCK-GM 349 
at SmaI site. The recombinant plasmid was then transferred into wild-type S. maltophilia 350 




was confirmed by PCR using primers smlt0009 full length FW (5’-352 
AAAGAATTCAGTAGGAATAACGCCTGAATGC-3’) and smlt0009 full length RV (5’-353 
AAAGAATTCTGACGCTTACCTTTGTTGTGTG-3’). 354 
Cloning smlt0009 and trans-complementation 355 
The smlt0009 gene and its promoter was amplified with Phusion High-Fidelity DNA 356 
Polymerase (NEB, UK) from S. maltophilia genomic DNA by using primers smlt0009 full 357 
length FW (5’-AAAGAATTCAGTAGGAATAACGCCTGAATGC-3’) and smlt0009 full length 358 
RV (5’-AAAGAATTCTGACGCTTACCTTTGTTGTGTG-3’). The PCR product was ligated 359 
into the vector pBBR1MCS at a SmaI site. The recombinant plasmid was then transferred 360 
into S. maltophilia cells by conjugation from E. coli SM10. The transconjugants were 361 
selected for chloramphenicol resistance and the presence of plasmids was confirmed by 362 
PCR using primers M13 FW (5’- GTAAAACGACGGCCAGT-3’) and M13 RV (5’-363 
CAGGAAACAGCTATGAC-3’). 364 
Proteomics 365 
500 µL of an overnight NB culture were transferred to 50 mL NB and cells were grown at 366 
37˚C to 0.6 OD600. Cells were pelleted by centrifugation (10 min, 4,000 × g, 4°C) and 367 
resuspended in 30 mL of 30 mM Tris-HCl, pH 8 and broken by sonication using a cycle of 1 368 
s on, 0.5 s off for 3 min at amplitude of 63% using a Sonics Vibracell VC-505TM (Sonics and 369 
Materials Inc., Newton, Connecticut, USA). The sonicated samples were centrifuged at 370 
8,000 rpm (Sorval RC5B PLUS using an SS-34 rotor) for 15 min at 4°C to pellet intact cells 371 
and large cell debris; For envelope preparations, the supernatant was subjected to 372 
centrifugation at 20,000 rpm for 60 min at 4°C using the above rotor to pellet total envelopes. 373 
To isolate total envelope proteins, this total envelope pellet was solubilised using 200 μL of 374 
30 mM Tris-HCl pH 8 containing 0.5% (w/v) SDS.  375 
Protein concentrations in all samples were quantified using Biorad Protein Assay Dye 376 




envelope protein analysis) were separated by SDS-PAGE using 11% acrylamide, 0.5% bis-378 
acrylamide (Biorad) gels and a Biorad Min-Protein Tetracell chamber model 3000X1. Gels 379 
were resolved at 200 V until the dye front had moved approximately 1 cm into the separating 380 
gel. Proteins in all gels were stained with Instant Blue (Expedeon) for 20 min and de-stained 381 
in water.  382 
The 1 cm of gel lane was subjected to in-gel tryptic digestion using a DigestPro automated 383 
digestion unit (Intavis Ltd).  The resulting peptides from each gel fragment were fractionated 384 
separately using an Ultimate 3000 nanoHPLC system in line with an LTQ-Orbitrap Velos 385 
mass spectrometer (Thermo Scientific). In brief, peptides in 1% (v/v) formic acid were 386 
injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After washing 387 
with 0.5% (v/v) acetonitrile plus 0.1% (v/v) formic acid, peptides were resolved on a 250 mm 388 
× 75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 389 
150 min organic gradient, using 7 gradient segments (1-6% solvent B over 1 min, 6-15% B 390 
over 58 min, 15-32% B over 58 min, 32-40% B over 5 min, 40-90% B over 1 min, held at 391 
90% B for 6 min and then reduced to 1% B over 1 min) with a flow rate of 300 nL/min.  392 
Solvent A was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic 393 
acid. Peptides were ionized by nano-electrospray ionization MS at 2.1 kV using a stainless-394 
steel emitter with an internal diameter of 30 μm (Thermo Scientific) and a capillary 395 
temperature of 250°C. Tandem mass spectra were acquired using an LTQ-Orbitrap Velos 396 
mass spectrometer controlled by Xcalibur 2.1 software (Thermo Scientific) and operated in 397 
data-dependent acquisition mode. The Orbitrap was set to analyze the survey scans at 398 
60,000 resolution (at m/z 400) in the mass range m/z 300 to 2000 and the top twenty 399 
multiply charged ions in each duty cycle selected for MS/MS in the LTQ linear ion trap. 400 
Charge state filtering, where unassigned precursor ions were not selected for fragmentation, 401 
and dynamic exclusion (repeat count, 1; repeat duration, 30 s; exclusion list size, 500) were 402 




40%; activation q, 0.25; activation time 10 ms; and minimum ion selection intensity, 500 404 
counts. 405 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 406 
(Thermo Scientific) and searched against the UniProt S. maltophilia strain K279a database 407 
(4365 protein entries; UniProt accession UP000008840) using the SEQUEST (Ver. 28 Rev. 408 
13) algorithm. Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance 409 
was set at 0.8 Da. Search criteria included carbamidomethylation of cysteine (+57.0214) as 410 
a fixed modification and oxidation of methionine (+15.9949) as a variable modification. 411 
Searches were performed with full tryptic digestion and a maximum of 1 missed cleavage 412 
was allowed. The reverse database search option was enabled and all peptide data was 413 
filtered to satisfy false discovery rate (FDR) of 5 %. The Proteome Discoverer software 414 
generates a reverse “decoy” database from the same protein database used for the analysis 415 
and any peptides passing the initial filtering parameters that were derived from this decoy 416 
database are defined as false positive identifications. The minimum cross-correlation factor 417 
filter was readjusted for each individual charge state separately to optimally meet the 418 
predetermined target FDR of 5 % based on the number of random false positive matches 419 
from the reverse decoy database. Thus, each data set has its own passing parameters. 420 
Protein abundance measurements were calculated from peptide peak areas using the Top 3 421 
method (Silva et al., 2006) and proteins with fewer than three peptides identified were 422 
excluded. The proteomic analysis was repeated three times for each parent and mutant 423 
strain, each using a separate batch of cells. Data analysis was as follows: all raw protein 424 
abundance data were uploaded into Microsoft Excel. Raw data from each sample were 425 
normalised by division by the average abundance of all 30S and 50S ribosomal protein in 426 
that sample. A one-tailed, unpaired T-Test was used to calculate the significance of any 427 
difference in normalised protein abundance data in the three sets of data from the parent 428 
strains versus the three sets of data from the mutant derivative. A p-value of <0.05 was 429 




compared to its parent was calculated using the averages of normalised protein abundance 431 
data for the three biological replicates for each strain.  432 
Siderophore Detection 433 
100 µL of an overnight culture in Cation-Adjusted Muller-Hinton Broth (CA-MHB) was used 434 
to set up a fresh subculture in 10 mL of CA-MHB which was then incubated until the OD600 435 
reached 0.5. Cells were centrifuged (4,000 x g, 10 min) and the resulting pellet was 436 
resuspended in 10 mL of Phosphate Buffered Saline (PBS) and centrifuged again (4,000 x g, 437 
10 min). The supernatant was discarded, and the pellet was again resuspended in fresh 438 
PBS (10 mL) and centrifuged (4,000 x g, 10 min). This washed bacterial pellet was then 439 
diluted in PBS to prepare a bacterial suspension of OD600 0.2. Ten microliters of the bacterial 440 
suspension were spotted on Chrome Azurol S (CAS) agar. CAS agar was made up mixing 441 
up 90 mL of MHA and 10 mL of freshly made CAS solution. 100 mL of the CAS solution was 442 
made up based on the following description: 60.5 mg of CAS in 50 mL of water, 72.9 mg of 443 
hexadecyltrimethyl ammonium bromide in 40 mL of water, and 10 mL of 1 mM FeCl3, 10 mM 444 
HCl) (Garcia et al., 2012). CAS agar control included 100 µM FeCl3 where no colour change 445 
was expected. 446 
Fluorescent Hoescht (H) 33342 dye accumulation assay  447 
Envelope permeability in living bacteria was tested using a dye accumulation assay protocol 448 
(Coldham et al., 2010) where the dye only fluoresces if it crosses the entire envelope and 449 
interacts with DNA. Overnight cultures (in NB) at 37°C were used to prepare NB subcultures, 450 
which were incubated at 37°C until a 0.6 OD600 was reached. Cells were pelleted by 451 
centrifugation (4000 rpm, 10 min) (ALC, PK121R) and resuspended in 500 µL of PBS. The 452 
optical densities of all suspensions were adjusted to 0.1 OD600. Aliquots of 180 µL of cell 453 
suspension were transferred to a black flat-bottomed 96-well plate (Greiner Bio-one, 454 
Stonehouse, UK). Eight technical replicates, for each strain tested, were in each column of 455 




incubated at 37°C. Hoescht dye (H33342, 250 µM in water) was added to bacterial 457 
suspension of the plate using the plate-reader’s auto-injector to give a final concentration of 458 
25 µM per well. Excitation and emission filters were set at 355 nm and 460 nm respectively. 459 
Readings were taken in intervals (cycles) separated by 150 s. 31 cycles were run in total. A 460 
gain multiplier of 1300 was used.  Results were expressed as absolute values of 461 
fluorescence versus time.   462 
Growth curves 463 
OD600 measurements of bacterial cultures were performed using a Spectrostar Nano 464 
Microplate Reader (BMG, Germany) in Costar Flat Bottom 96-well plates. Overnight cultures 465 
(in NB) were adjusted to OD600 = 0.01 and 200 µL of the diluted culture were taken to the 466 
plate together with a blank, NB. The plate was incubated at 37°C with double orbital shaking 467 
and OD600 was measured every 10 min for 24 h. 468 
Indirect ceftazidime uptake assay 469 
Overnight cultures of the strains being assayed for ceftazidime uptake were sub-cultured in 470 
NB to 0.5-0.7 OD600 and bacteria pelleted by centrifugation. Pellets were resuspended in NB 471 
to a density of 1.0 OD600 and ceftazidime (5 µg.mL-1 or 10 µg.mL-1) was introduced. After 24 472 
h incubation at 37°C with shaking, bacteria were pelleted and 10 µL of filter sterilized (0.2 473 
µm pore) supernatant were spotted on a freshly spread lawn of E. coli DH5α, using MHA, 474 
and made as if for disc susceptibility testing (CLSI 2006). The plate was incubated for 20 h 475 
at 37°C and zones of inhibition were measured using a ruler. To calibrate the assay, relating 476 
inhibition zone diameter to ceftazidime concentration, fixed concentrations of ceftazidime 477 
were made in NB and spotted onto the E. coli lawn and incubated and the inhibitions zones 478 
measured as above. 479 
 480 
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Table 1. Comparison of MICs (µg.mL-1) of ceftazidime and lactivicin derivatives 501 
against S. maltophilia ceftazidime and lactivicin mutants and the levels of β-lactamase 502 
produced. 503 
 504 




MIC of  
LTV-13 
MIC of  
LTV-17 
K279a 0.02±0.004 4 64 0.03 
M1 0.02±0.002 256 128 0.5 
M52 0.04±0.013 256 128 0.5 
KLTV 0.05±0.005 256 64 0.25 
K279a ∆smlt0009 0.01±0.002 128 128 0.5 
K279a mpl 0.72 ± 0.01 64 ND ND 
    
β-Lactamase activity was determined using nitrocefin hydrolysis (nmol.min-1.µg-1) in cell 505 
extracts from bacteria grown in the absence of antibiotic. Data for the β-lactamase hyper-506 
producing K279a mpl are taken from Calvopiña & Avison, 2018. 507 
Shaded MIC values represent a more than two doubling reduced susceptibility in reference 508 
to K279a and in the case of ceftazidime, shading show clinical resistance according to CLSI 509 
breakpoints. ND, Not Determined 510 
 511 




Table 2. MICs (µg.mL-1) of lactivicin derivatives against S. maltophilia clinical isolates 513 
with different Smlt0009 sequences 514 
Isolate Smlt0009 sequence  
(as compared with K279a) 
LTV-13 MIC LTV-17 MIC 
K279a Wild-type (by definition) 64 0.03 
10 N169S, A209T 128 0.03 
12 Wild-type 64 0.03 
14 Wild-type 64 0.03 
16 Wild-type 64 0.03 
17 Wild-type 64 0.03 
19 Wild-type 128 0.06 
21 Wild-type 64 0.03 
22 Wild-type 128 0.03 
23 N169S, A209T 256 0.03 
26 N169S, A209T 64 0.03 
27 N169S, A209T 128 0.06 
28 Wild-type 64 0.03 
29 Wild-type 64 0.03 
30 N169S, A209T 128 0.03 
31 Insertion of Proline between 
P69 and P70 
128 0.25 
32 N169S, A209T 128 0.13 
35 N169S, A209T 64 0.06 
36 Wild-type 64 0.03 
37 Wild-type 64 0.06 
39 Wild-type 128 0.03 
40 N169S, A209T 64 0.03 
43 Wild-type 128 0.06 
 515 
 516 




Figure Legends 518 
 519 
Figure 1. β-Lactam susceptibilities of ceftazidime resistant mutants versus K279a.  520 
In (A) growth inhibition zone diameters (mm) versus ceftazidime resistant mutants (M1 and 521 
M52) the LTV-17 resistant mutant (KLTV) and K279a Δsmlt0009 are reported in comparison 522 
with the parental strain (K279a). Smaller zone diameters mean reduced susceptibility. The 523 
following antibiotics were tested, with the amounts present in each disc noted: cefoxitin (FOX 524 
30 µg), ceftazidime (CAZ 30 µg), cefepime (FEP 30 µg), piperacillin-tazobactam (TZP 110 525 
µg), doripenem (DOR 10 µg), meropenem (MEM 10 µg). In (B) the inhibition zone diameters 526 
versus K279a and mutants carrying control plasmid (pBBR1MCS), white bar (p), or 527 
pBBR1MCS::smlt0009 black bar (pSmlt0009), where smlt0009 mutation is complemented in 528 
trans, are reported. Zones of inhibition around a CAZ (30 µg) disc are reported as mean 529 
values, n=3. Error bars represent standard error of the mean (SEM). Zone diameters are 530 
measured across the disc, so the minimum zone diameter is 6 mm, which is the diameter of 531 
the disc. 532 
 533 
Figure 2. Sequence of Smlt0009 in ceftazidime resistant mutants and impact on 534 
growth and permeability phenotypes. 535 
(A) is an alignment of translated high fidelity PCR sequences that confirmed mutation in the 536 
proline-rich region in ceftazidime resistant mutants M1, M52 and KLTV. Alignment was 537 
performed with CLUSTAL Omega and GeneDoc, showing amino acids 61-96; all other 538 
residues are identical across the variants. (B) reports the rate of fluorescent dye 539 
accumulation, which is reduced in all smlt0009 mutants relative to K279a (p<0.0001 based 540 
on a T-test at 15 cycles), but greater in M1 than the other mutants (p<0.01 at 15 cycles). The 541 
assay followed injection of Hoescht (H) 33342 dye (25 µM final) to a cell suspension of 0.1 542 




three biological replicates with four technical replicates for each biological replicate. Error 544 
bars represent one Standard Deviation (SD). (C) reports growth inhibition zone diameters 545 
(mm) versus smlt0009 mutants in comparison with K279a. Smaller zone diameters mean 546 
reduced susceptibility. Non-β-lactams tested were with the amount in each disc noted: 547 
amikacin (AK 30 µg), ciprofloxacin (CIP 5 µg), norfloxacin (NOR 10 µg), tigecycline (TGC 15 548 
µg), minocycline (MH 30 µg), trimethoprim-sulfamethoxazole (SXT 25 µg), chloramphenicol 549 
(C 30 µg). Zones of inhibition are reported as mean values, n=3. Error bars represent SEM. 550 
Zone diameters are measured across the disc, so the minimum zone diameter is 6 mm, 551 
which is the diameter of the disc. (D) reports growth curves for K279a and the smlt0009 552 
mutants in NB over 24 h. The curves show OD600 versus time. Each curve plots mean data 553 
for eight replicates. Error bars represent one SD. 554 
 555 
Figure 3. Increased siderophore production in ceftazidime resistant mutants versus 556 
K279a. 557 
(A) Protein abundance data for EntB (Uniprot: B2FHQ4) derived from LC-MS/MS proteomics 558 
analysis were normalised using the average abundance of 30S and 50S ribosomal proteins 559 
in each sample. Values are reported as mean +/- SEM (n=3). In each case the change 560 
relative to K279a in each mutant is statistically significant (p<0.05). Full proteomics data are 561 
shown Tables S1-S3. (B) illustrates the diffusion of siderophore produced by K279a and 562 
smlt0009 mutants. Diffusion of siderophore can be seen after spotting 10 µL of a PBS 563 
washed bacterial suspension (OD600 0.2) onto a modified CAS agar. The image is 564 
representative of three experiments. (C) reports the diameter of diffusion of siderophore 565 
produced by strains tested as in (B). Values are reported as mean +/- SEM of three 566 






Figure 4 Reduced uptake of ceftazidime in smlt0009 mutants. 570 
In (A) a standard curve is reported, where fixed concentrations of ceftazidime (made in NB) 571 
were applied to a freshly spread lawn of E. coli DH5α on an MHA plate in 10 µL spots, with 572 
the zone of growth inhibition being measured following 20 h of growth at 37°C. Zone of 573 
growth inhibition was then plotted versus the ceftazidime concentration applied. Data are 574 
means (n=3). The regression (solid line) with 95% confidence intervals (dashed line) was 575 
fitted with an R2 of 0.99. (B) shows zones of inhibition in the E. coli DH5α lawn, incubated as 576 
in (A) but after spotting 10 µL of clarified (by centrifugation) and filter-sterilized culture 577 
medium that remained following 24 h of growth of S. maltophilia K279a or the four smlt0009 578 
mutant derivatives, initially inoculated in the presence of 10 µg.mL-1 of ceftazidime. This 579 
image is representative of three experiments and the zone diameter is correlated with the 580 
concentration of ceftazidime remaining in the culture medium. (C) reports mean data (n=3) 581 
+/- SEM for the concentrations of ceftazidime remaining in these culture media, calculated 582 
by spotting each culture medium onto an E. coli DH5α lawn as in (B). The zones of inhibition 583 
measured were used to estimate the concentration of ceftazidime present in each culture 584 
medium applied to the lawn by reference to standard curve presented in (A). Data in (C) 585 
show values for experiments using S. maltophilia cultures inoculated initially in the presence 586 
of 5 µg.mL-1 or 10 µg.mL-1 ceftazidime. In all cases, concentrations in the supernatants of 587 
cultures growing mutants were greater than those growing K279a (p<0.01 based on a Mann-588 
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